Saxenda for weight loss: what the FDA approval actually means

What's this video probably claiming?

Based on the caption and hashtags, this pharmacy-affiliated TikTok account is promoting Saxenda (liraglutide 3 mg) as an FDA-approved injectable weight loss medication for adults and adolescents aged 12 and older with obesity or overweight accompanied by weight-related health conditions like hypertension or type 2 diabetes. The creator is likely walking through the drug's active ingredient, its mechanism, and its approved indications. The framing appears educational and tied to pharmacy services, with hashtags like صيدلية (pharmacy) and تنزيل_الوزن (weight loss) suggesting a product-adjacent post. This is a real drug with real approvals, so the foundation here is largely legitimate. The question is whether the nuance around who qualifies, what results actually look like, and where Saxenda sits in the current GLP-1 landscape gets the attention it deserves.

What does the science actually show?

Liraglutide 3 mg (Saxenda) received FDA approval for chronic weight management in adults in 2014 and for adolescents aged 12 and older in 2020. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed adults on liraglutide 3 mg lost an average of 8.4% of body weight over 56 weeks versus 2.8% on placebo. More patients on liraglutide achieved at least 5% weight loss (63.2% vs 27.1%). The adolescent SCALE trial (Kelly et al., 2020, NEJM) showed a BMI standard deviation score reduction of 0.22 versus an increase of 0.22 on placebo. These are statistically significant results, but they are modest compared to what semaglutide 2.4 mg (Wegovy) now delivers, roughly 15-17% body weight reduction in the STEP 1 trial (Wilding et al., 2021, NEJM). Liraglutide also requires daily injections, a practical disadvantage against weekly semaglutide.

Where does the social media noise diverge from clinical reality?

Pharmacy promotion posts for Saxenda in 2024 and 2025 risk glossing over a few inconvenient realities. First, Saxenda is now a second-line GLP-1 option in most clinical guidelines, with semaglutide and tirzepatide producing superior weight loss outcomes in head-to-head and comparative data. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide achieving up to 22.5% body weight reduction. Second, the adolescent indication is often promoted without adequate discussion of the requirement for a BMI at or above the 95th percentile plus at least one comorbidity, a real clinical threshold that rules out casual use. Third, side effect profiles, primarily nausea, vomiting, and the rare but serious risk of pancreatitis, rarely get airtime in promotional pharmacy content. Thyroid C-cell tumor risk, while seen in rodents and warranting a boxed warning, is another detail that tends to disappear in short-form content.

What should you actually know?

Saxenda is a legitimate, regulated medication with real clinical trial support. If you are considering it, a few things matter. Daily subcutaneous injections are required, titrated from 0.6 mg up to the 3 mg maintenance dose over several weeks. It is not a standalone solution. The SCALE trials combined liraglutide with a reduced-calorie diet and increased physical activity, meaning the drug works in a structured program, not in isolation. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use it. Contraindication is not a footnote. In the current market, patients and prescribers also need an honest conversation about whether liraglutide is the right starting point given the availability of more effective weekly options. A telehealth or pharmacy consultation should include that discussion, not just a product walkthrough.